Enzo Biochem (ENZ, $3.75) posts +62% year-over-year revenue growth

Enzo Biochem  posted a strong increase in revenue for its fiscal 2021 second quarter, ended Jan. 31, amid strong demand  for the life sciences’ company’s testing equipment amid COVID-19 pandemic.

Revenue climbed +62% year-over-year to $31.5 million in the quarter. The company’s earnings came in at 5 cents a share, compared to a year-ago loss of - 16 cents a share.

“Our open system approach allows for the highest levels of flexibility and adaptability in the post COVID-19 environment,” Barry Weiner, Enzo’s president, said. "Our GENFLEX platform enables laboratories to use third-party or their own reagents on this open platform with ease and flexibility."

The company announced that founder Elazar Rabbani is stepping down as CEO. However, Rabbani would a director.

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.